JP2021512893A5 - - Google Patents
Info
- Publication number
- JP2021512893A5 JP2021512893A5 JP2020542546A JP2020542546A JP2021512893A5 JP 2021512893 A5 JP2021512893 A5 JP 2021512893A5 JP 2020542546 A JP2020542546 A JP 2020542546A JP 2020542546 A JP2020542546 A JP 2020542546A JP 2021512893 A5 JP2021512893 A5 JP 2021512893A5
- Authority
- JP
- Japan
- Prior art keywords
- theta
- degrees
- approximately
- polymorph
- ray powder
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862628194P | 2018-02-08 | 2018-02-08 | |
| US62/628,194 | 2018-02-08 | ||
| PCT/US2019/017117 WO2019157225A2 (en) | 2018-02-08 | 2019-02-07 | Certain chemical entities, compositions, and methods |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021512893A JP2021512893A (ja) | 2021-05-20 |
| JP2021512893A5 true JP2021512893A5 (https=) | 2022-02-16 |
| JPWO2019157225A5 JPWO2019157225A5 (https=) | 2022-02-16 |
| JP7550646B2 JP7550646B2 (ja) | 2024-09-13 |
Family
ID=67549574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542546A Active JP7550646B2 (ja) | 2018-02-08 | 2019-02-07 | 特定の化学物質、組成物、および方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11465975B2 (https=) |
| EP (1) | EP3749310B1 (https=) |
| JP (1) | JP7550646B2 (https=) |
| KR (1) | KR20200143361A (https=) |
| CN (1) | CN112105365A (https=) |
| AU (1) | AU2019218893B2 (https=) |
| CA (1) | CA3090528A1 (https=) |
| IL (1) | IL276476B2 (https=) |
| PH (1) | PH12020551193A1 (https=) |
| SG (1) | SG11202007492XA (https=) |
| WO (1) | WO2019157225A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4255434A4 (en) * | 2020-12-02 | 2024-10-23 | Neupharma, Inc. | CERTAIN CHEMICALS, COMPOSITIONS AND PROCESSES |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| CN1087725C (zh) | 1994-03-25 | 2002-07-17 | 同位素技术有限公司 | 用氘代方法增强药物效果 |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| BR9707495A (pt) | 1996-02-13 | 1999-07-27 | Zeneca Ltd | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente |
| US6291455B1 (en) | 1996-03-05 | 2001-09-18 | Zeneca Limited | 4-anilinoquinazoline derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| SK288365B6 (sk) | 1999-02-10 | 2016-07-01 | Astrazeneca Ab | Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy |
| NZ522074A (en) | 2000-05-31 | 2004-06-25 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| IL153484A0 (en) | 2000-07-07 | 2003-07-06 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
| CN1255392C (zh) | 2000-07-07 | 2006-05-10 | 安吉奥金尼药品有限公司 | 作为血管生成抑制剂的秋水仙醇衍生物 |
| CN103702990B (zh) * | 2011-07-27 | 2015-09-09 | 阿斯利康(瑞典)有限公司 | 2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用于治疗癌症 |
| CA2846574C (en) * | 2011-08-26 | 2020-07-07 | Neupharma, Inc. | Quinoxaline sulfonamide derivates for use as kinase inhibitors |
| CN105209456B (zh) * | 2013-03-06 | 2018-05-08 | 阿斯利康(瑞典)有限公司 | 表皮生长因子受体的活化突变形式的喹唑啉抑制剂 |
| AU2014308616B2 (en) * | 2013-08-23 | 2018-12-06 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| US10689359B2 (en) * | 2015-12-25 | 2020-06-23 | Xuanzhu Pharma Co., Ltd. | Crystals of quinazoline derivative and preparation method therefor |
-
2019
- 2019-02-07 SG SG11202007492XA patent/SG11202007492XA/en unknown
- 2019-02-07 WO PCT/US2019/017117 patent/WO2019157225A2/en not_active Ceased
- 2019-02-07 US US16/967,696 patent/US11465975B2/en active Active
- 2019-02-07 CN CN201980024284.9A patent/CN112105365A/zh active Pending
- 2019-02-07 JP JP2020542546A patent/JP7550646B2/ja active Active
- 2019-02-07 EP EP19751367.4A patent/EP3749310B1/en active Active
- 2019-02-07 AU AU2019218893A patent/AU2019218893B2/en active Active
- 2019-02-07 KR KR1020207025874A patent/KR20200143361A/ko active Pending
- 2019-02-07 CA CA3090528A patent/CA3090528A1/en active Pending
- 2019-02-07 IL IL276476A patent/IL276476B2/en unknown
-
2020
- 2020-08-06 PH PH12020551193A patent/PH12020551193A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI619694B (zh) | 用於製備喹啉衍生物之方法 | |
| TWI704142B (zh) | 抗癌劑1-((4-(4-氟-2-甲基-1h-吲哚-5-基氧基)-6-甲氧基喹啉-7-基氧基)甲基)環丙胺的製備方法、及其藥物的結晶形及其鹽類 | |
| TWI417292B (zh) | ２-甲基-２-〔４-（３-甲基-２酮-８-喹啉-３-基-２，３-二氫-咪唑并〔４，５-ｃ〕喹啉-１-基）-苯基〕-丙腈之鹽及結晶型式 | |
| EP3248983B1 (en) | Crystal form a of obeticholic acid and preparation method therefor | |
| JP6170146B2 (ja) | チロシンキナーゼ阻害剤二マレイン酸塩のｉ型結晶およびその製造法 | |
| JP3665053B2 (ja) | 純結晶形態の５−クロロ−３−（４−メタンスルホニルフェニル）−６’−メチル−［２，３’］ビピリジニルおよび合成方法 | |
| CA2588398A1 (en) | Potassium salt of an hiv integrase inhibitor | |
| TWI705060B (zh) | 一種ｍｅｋ激酶抑制劑的對甲苯磺酸鹽、其結晶形式及製備方法 | |
| EP1919893A2 (en) | Polymorphic forms of imatinib mesylate and processes for their preparation as well as of amorphous imatinib mesylate and form alpha | |
| TWI772424B (zh) | 一種苯并呋喃類衍生物游離鹼的晶型及製備方法 | |
| EP3283491A1 (en) | New forms of ixazomib citrate | |
| WO2018007927A1 (en) | Process for preparation of palbociclib | |
| JP2021512893A5 (https=) | ||
| US6521642B2 (en) | 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis | |
| TW202024078A (zh) | Bet溴結構域(bromodomain)抑制劑之固體形式之製備方法 | |
| WO2019037591A1 (zh) | 盐酸美法仑晶型及其制备方法与应用 | |
| TW201625582A (zh) | 製備吡蟲啉（ｉｍｉｄａｃｌｏｐｒｉｄ）多晶型的方法 | |
| JPWO2019157225A5 (https=) | ||
| US20020147221A1 (en) | 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3]bipyridinyl in pure crystalline form and process for synthesis | |
| WO2023068253A1 (ja) | ベンゾチオフェン化合物の新規結晶形及びその製造方法 | |
| US20110184067A1 (en) | O-desmethylvenlafaxine succinate polymorph & process for preparing thereof | |
| EP2019113A1 (en) | New Crystalline Salts of 5-Amino-3-(2',3'-di-O-acetyl-beta-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one | |
| CN101448796B (zh) | 盐及其晶体改性 | |
| EP1768969B1 (en) | Crystalline mycophenolate sodium | |
| WO2015163446A1 (ja) | イミダゾール化合物の製造方法 |